Home   >> Scientific Program

Scientific Program

GMT+8

3 JUNE FRI

14:00-15:30

Postgraduate course - Portal hypertension

14:00-14:20

Introduction of portal hypertension: definition and classification

Juan Carlos Garcia - PAGAN, Barcelona

14:20-14:40

Cirrhotic portal hypertension: evaluation and staging

Mattias MANDORFER, Vienna

14:40-15:00

Non-cirrhotic portal hypertension: diagnostic approach

Ashish KUMAR, New Delhi

15:00-15:20

Rare causes of portal hypertension: hematological and vascular causes

Jiyao WANG, Shanghai

15:20-15:30

Discussion

15:30-17:00

Postgraduate course - Portal hypertension and decompensation

15:30-15:50

Prophylaxis of variceal hemorrhage in patients with cirrhosis: Endoscopic Approach

Shutian ZHANG, Beijing

15:50-16:10

Management of ascites in decompensated cirrhosis

Paolo ANGELI, Padova

16:10-16:30

New concept and management of acute kidney injury

Samuel S. LEE, Palo Alto, CA

16:30-16:50

Targeting and immunotherapy of HCC in cirrhotic patients

Kwang-Hyub HAN, Seoul

16:50-17:00

Discussion


GMT+8

3 JUNE FRI

18:00-20:00

State-of-the-art 1 

18:00-18:30

Mechanisms of portal hypertension and regression 

Jordi Gracia-SANCHO, Barcelona

18:30-19:00

Therapies of portal hypertension and regression

Weifen XIE, Beijing

19:00-20:00

Consensus on regression of portal hypertension

Jordi Gracia-SANCHO, Barcelona

GMT+8

4 JUNE SAT

09:00-10:00

State-of-the-art 2 

09:00-09:30

Mechanisms of fibrosis resolution and liver regeneration 

David BRENNER, San Diego

09:30-10:00

Cirrhotic portal hypertension: evaluation and staging

Guadalupe Garcia-TSAO, New Heaven

18:00-19:00

State-of-the-art 3

18:00-18:30

Non-invasive assessment of clinically significant portal hypertension 

Shiv K. SARIN, New Delhi

18:30-19:00

Non-invasive assessment of liver fibrosis- From research to clinical practice

Laurent CASTERA, Clichy

GMT+8

5 JUNE SUN

09:00-10:00

State-of-the-art 4 

09:00-09:30

Clinical trials related to liver fibrosis: What have we learnt from the past 

Anna S.F. LOK, Ann Arbor, MI

09:30-10:00

Clinical implications of experimental research: What we can do in future

Scott FRIEDMAN, New York

18:00-19:00

State-of-the-art 5

18:00-18:30

Molecular and cellular perspectives of liver fibrosis: Future therapy 

Detlef SCHUPPAN, Mainz

18:30-19:00

Endpoint choice for clinical trials in CHB 

George LAU, Hong Kong SAR



GMT+8

4 JUNE SAT

5 JUNE SUN

10:00-11:30

Session 1. Histological diagnosis and staging of liver fibrosis

Session 5. Etiological management - Viral hepatitis

10:00-10:20

Histological assessment of fibrosis and cirrhosis: revised Laennec staging system

Ian R. WANLESS, Halifax

Novel targets for HBV treatment

Wenhui LI, Beijing

10:20-10:40

Viral hepatitis: biopsy grading, staging and beyond

Neil D. THEISE, New York

Clinical trials aimed at HBV cure: present and future

Calvin Q Pan , New York

10:40-11:00

NAFLD: Histopathologic feature and staging

David E KLEINER, Bethesda, MD

HCC risk prediction model for HBV patients on antiviral therapy

Hwai-I YANG, Taipei

11:00-11:20

Fully histological quantification/AI of fibrosis in clinical trial

Aileen WEE, Singapore

Treatment of fibrosis: benefits beyond HCV cure

Lai WEI, Beijing

11:20-11:30

Discussion

Discussion

11:30-13:00

Session 2. Non-invasive assessment - Serum biomarkers

Session 6. Etiological management - Metabolic associated fatty liver disease

11:30-11:50

Conventional biomarkers for liver fibrosis in clinical practice: present and future

Grace L. H. WONG, Hong Kong SAR

From NAFLD to MAFLD

Tawesak TANWANDEE, Bangkok

11:50-12:10

Markers directly related to fibrogenesis and fibrolysis
Tatiana KISSELEVA, San Diego, California

Lean NASH and liver fibrosis
Vincent Wai-Sun WONG, Hong Kong SAR

12:10-12:30

Novel biomarkers and matrisome of liver fibrosis

Wei CHEN, Beijing

Lifestyle modification of MAFLD patients
Jiangao FAN, Shanghai

12:30-12:50

Can serum markers be used for as a surrogate endpoint for clinical trial

Hong YOU, Beijing

Treatment targets for Nonalcoholic Steatohepatitis
Arun J SANYAL, Richmond, VA

12:50-13:00

Discussion

Discussion

13:00-14:00

Satellite Symposium / Free Paper

Satellite Symposium / Free Paper

14:00-15:30

Session 3.  Imaging technology

Session 7 Etiological management - Autoimmune and DILI

14:00-14:20

Transient elastography (TE) for advanced chronic liver disease

Seung Up KIM, Seoul

Updates management of drug-induced liver injury: 2021 APASL guidelines

Yimin MAO, Shanghai

14:20-14:40

MRI and MRE assessment for chronic liver disease

Zhenghan YANG, San Diego

Primary Biliary Cholangitis: 2021 Practice Guidance Update from APASL

Atsushi TANAKA , Tokyo

14:40-15:00

Hepatic venous pressure gradient (HVPG) for clinical practice

Guohong HAN, Xi’an

New advances in autoimmune hepatitis

Xiong MA, Shanghai

15:00-15:20

Radiomics signature for assessment in portal hypertension

Xiaolong QI, Lanzhou

New advances in PSC and IgG4 related cholangitis 

Ying HAN, Xi’an

15:20-15:30

Discussion

Discussion

15:30-17:00

Session 4. Traditional medicine in liver fibrosis

Session 8 Research and trials: Novel pharmaceutical targets

15:30-15:50

Mechanism of traditional Chinese medicine to treat liver fibrosis

Chenghai LIU, Shanghai

New targets for liver fibrosis

Don C  Rockey, Charleston, SC

15:50-16:10

Evidence of TCM for HBV related fibrosis and cirrhosis
Yongping YANG, Beijing 

New design for liver fibrosis
Jidong JIA, Beijing

16:10-16:30

Methodological consideration for traditional medicine research

Jianping LIU, Beijing

Role of liver fibrosis assessment in HCC risk prediction for chronic hepatitis B
Henry Lik-Yuen CHAN, Hong Kong SAR

16:30-16:50

Clinical care and research of liver disease: impact of COVID19 epidemics 

Wenhong ZHANG, Shanghai

New treatment for portal hypertension
Han-Chieh LIN, Taipei

16:50-17:00

Discussion

Discussion

17:00-18:00

Satellite Symposium / Free Paper

Satellite Symposium / Free Paper